Digital health firm Eko has closed a Series B funding round to support the development of an artificial intelligence (AI)-based solution for cardiac screening and analysis.

ARTIS Ventures led the $20m financing round. Mayo Clinic, DigiTx Partners, 3M Ventures, NTT Venture Capital (NTTVC), Seraph Group and XTX Ventures also participated.

Eko intends to use the funds to research, develop and commercialise the AI platform, which will leverage machine learning technology.

Eko CEO Connor Landgraf said: “Artificial intelligence is arguably one of the most powerful advancements in modern medicine, enabling clinicians to predict with more accuracy, diagnose with more confidence and in the end, give their patients the best care possible.

“We will use this funding to drive more research and continue the development of data-driven technology to help physicians detect and monitor patients with heart disease that may otherwise be missed.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The company created a cardiac monitor that uses a digital stethoscope and ECG technology for in-clinic, as well as at-home monitoring. Patients can use the monitor to send cardiac data to their physicians.

Furthermore, Eko is working with both medical device and pharmaceutical firms to develop therapy and data combinations, which focus on personalised cardiac care.

The company is also engaged in clinical research for developing algorithms based on datasets for specific conditions, such as atrial fibrillation, valvular heart disease, congestive heart failure and structural heart disease.

Eko and Mayo Clinic partnered for the development and commercialisation of a machine learning algorithm to screen patients for a low ejection fraction or a weak heart pump.

With Northwestern Medicine, the company will study machine learning for the screening of valvular heart disease. The collaboration may expand in the future.

Furthermore, Sutter Health in Northern California has deployed Eko’s enterprise software to link cardiologists in Sacramento with patients visiting rural clinics for ongoing cardiology services.